Health Care & Life Sciences » Pharmaceuticals | Summit Therapeutics PLC

Summit Therapeutics PLC | Cash Flow

Fiscal year is February-January. All values GBP Thousands.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
6,700.00
12,660.00
23,195.00
25,707.00
10,893.00
5,031
Depreciation, Depletion & Amortization
26.00
33.00
48.00
58.00
246.00
1,138
Other Funds
-
-
-
23.00
-
6,063
Funds from Operations
6,260.00
10,941.00
17,892.00
19,683.00
6,577.00
12,232
Changes in Working Capital
400.00
333.00
740.00
31,832.00
8,100.00
39,023
Net Operating Cash Flow
5,860.00
11,274.00
17,152.00
12,149.00
14,677.00
26,791
Capital Expenditures
47.00
35.00
66.00
88.00
479.00
Sale of Fixed Assets & Businesses
102.00
-
-
-
-
Net Investing Cash Flow
55.00
35.00
66.00
88.00
5,254.00
Net Financing Cash Flow
4,456.00
20,544.00
22,136.00
413.00
13,905.00
Net Change in Cash
1,349.00
9,235.00
5,039.00
11,758.00
7,960.00
Free Cash Flow
5,897.00
11,309.00
17,218.00
12,068.00
15,037.00
Net Assets from Acquisitions
-
-
-
-
4,775.00
Change in Capital Stock
4,456.00
20,544.00
22,136.00
390.00
13,905.00
Exchange Rate Effect
-
-
121.00
716.00
1,934.00

About Summit Therapeutics

View Profile
Address
136a Eastern Avenue
Abingdon Oxfordshire OX14 4SB
United Kingdom
Employees -
Website http://summitplc.com
Updated 07/08/2019
Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection. The company was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, United Kingdom.